Emcure Pharmaceuticals Limited (BOM:544210)

Market Cap	264.06B
Revenue (ttm)	81.81B
Net Income (ttm)	7.44B
Shares Out	n/a
EPS (ttm)	39.35
PE Ratio	35.48
Forward PE	26.75
Dividend	3.00 (0.22%)
Ex-Dividend Date	Aug 14, 2025

Volume	2,971
Average Volume	6,137
Open	1,380.95
Previous Close	1,345.35
Day's Range	1,341.20 - 1,393.10
52-Week Range	890.00 - 1,524.85
Beta	n/a
RSI	54.86
Earnings Date	Nov 7, 2025

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.

• Industry: Pharmaceutical Preparations
• Founded: 1981
• Employees: 6,731
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 544210

Financial Performance

In 2024, Emcure Pharmaceuticals's revenue was 78.96 billion, an increase of 18.59% compared to the previous year's 66.58 billion. Earnings were 6.81 billion, an increase of 36.76%.